Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption.
| Autor: | Papasavvas E; The Wistar Institute, Philadelphia., Azzoni L; The Wistar Institute, Philadelphia., Ross BN; The Wistar Institute, Philadelphia., Fair M; The Wistar Institute, Philadelphia., Howell BJ; Merck, Inc., West Point., Hazuda DJ; Merck, Inc., West Point., Mounzer K; Jonathan Lax Immune Disorders Treatment Center, Philadelphia Field Initiating Group for HIV-1 Trials., Kostman JR; John Bell Health Center, Philadelphia Field Initiating Group for HIV-1 Trials., Tebas P; University of Pennsylvania, Department of Medicine, Philadelphia, Pennsylvania, USA., Montaner LJ; The Wistar Institute, Philadelphia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | AIDS (London, England) [AIDS] 2021 Oct 01; Vol. 35 (12), pp. 2051-2054. |
| DOI: | 10.1097/QAD.0000000000002961 |
| Abstrakt: | We report on the post-hoc analysis of three clinical studies (NCT01935089, NCT00594880 and NCT00051818) with chronically HIV-infected, immune-reconstituted individuals with similar entry criteria, and demographics interrupting antiretroviral therapy (ART) without or with 5 weeks of weekly pegylated (Peg)-IFN-α2b or Peg-IFN-α2a immunotherapy added onto ART. Results show similar rates of viral suppression between both immunotherapies when continued during a 4-week ART interruption, despite Peg-IFN-α2a maintaining significantly higher trough blood levels. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|